

# **A Multiple Comparison Procedure for Hypotheses with Gatekeeping Structures**

Xiaolong Luo, Ph.D., MBA, Gary Chen, Ph.D., S. Peter Ouyang, Ph.D. Celgene Corporation

> Bruce W. Turnbull, Ph.D. Cornell University

**BASS XIX**Savannah, Georgia, November 6, 2012

1

# **Outline**

- A clinical trial example
- Problem Set-up

- •Proposed procedure
- Comparison with alternative procedures
- Application to the clinical trial
- Conclusions

#### **A Clinical Trial\***

- **Population: Patients with psoriasis**
- **Treatments: 1:1:1:1 randomization**
	- **Placebo (P)**
	- **Low dose regimen (L)**
	- **Medium dose regimen (M)**
	- **High dose regimen (H)**
- •**Endpoints**

•

Celgene

•

- **1. PASI change from baseline at week 24**
- **2.sPGA change from baseline at week 24**
- $\bullet$  **Objectives with strong control of FWER** 
	- **1. Claim significant improvement in PASI change for one or more dose groups**
	- **2. Claim significant improvement in sPGA change for significant dose group(s)**
- •**Sample size: 280 = 4 x 70**

\* Some design features and data are modified for illustrative purpose.

## **Statistical Problem**



•**Data**

Celgene

- **H <sup>γ</sup>l: <sup>π</sup> <sup>γ</sup><sup>l</sup> = 0 l**the contract of the contract of
- **Individual Z-scores**

$$
Y_{\nu}^{l} = \sum_{j=1}^{n_{l}} Y_{\nu,j}^{l}, l = 0,1,..., K; \nu = 1,2,..., p
$$
  

$$
Z_{\nu}^{l} = \sqrt{\frac{K+1}{N_{\nu}}} (Y_{\nu}^{l} - Y_{\nu}^{0}), l = 1,..., K; \nu = 1,2,..., p
$$

 $=$  U I A V  $=$ 

ˆ

- **Which of {H <sup>γ</sup>l: γ=1,2; l=1,2,3} can be rejected with a strong**   $\left( \sqrt{\frac{1}{\sigma^2} + \pi} \pi_{\nu l}, \hat{\sigma} \right)$  $Z_v^l \prec n(\sqrt{\frac{N}{\sigma^2 - 1}} \pi_{vl}, \hat{\sigma}_{vl}^2 + \hat{\sigma}_{vol}^2)$ *N* $\quad$  control at one-sided 2.5%  $\qquad \qquad ^\sim \qquad \qquad ^\sim \qquad \qquad ^\sim \qquad \qquad ^\sim \qquad V$ **significant level?**   $K + 1$ <sup>l</sup>  $\frac{1}{\nu l}$ ,  $\frac{1}{\nu l}$  i  $\frac{1}{\nu l}$  $\bigvee$   $K+1$   $\bigvee$   $\bigvee$
- • **No normality assumption for PASI and sPGA changes**  $\frac{1}{\sqrt{2}}Z_{V}^{i} > Z_{vl}$ ˆ $(\sqrt{\frac{1}{\hat{\sigma}^2_{vl}+\hat{\sigma}^2_{v0}}})$ 2  $\Delta$  2  $\rightarrow$   $\sim$   $\sqrt{l}$ *l l*  $p_{\nu l} = P(\sqrt{\frac{2}{\hat{\sigma}_{\nu l}^2 + \hat{\sigma}_{\nu 0}^2}} Z_{\nu}^l > z_{\nu l})$  $+\hat{\sigma}_{\nu 0}^2$   $Z_{\nu}^2 >$ =  $\mathbf{v} = \mathbf{v}$  **of the set of**  $\mathbf{v} = \mathbf{v}$

#### **Some Available MCPs**

- For the combined family of  $F_1$  and  $F_2$ , use weighted **bonferroni procedures (or graphical representation)**
	- **Bretz, Maurer, and Hommel 2011 SIM**

- Use Bonferroni for  $\mathsf{F}_1$  and  $\mathsf{F}_2$  individually, and then **mix them for the combined family with a bonferroni mixing function** 
	- **Dmitrienko and Tamhane (2011) SIM**
- Use truncated Hommel test for  $F_1$  and  $F_2$  individually, **and then mix them for the combined family with <sup>a</sup> bonferroni mixing function**
	- **Brechenmacher, Xu, Dmitrienko, Tamhane, A.C. (2011) JPS**

#### **Points for Consideration**

- • **Many MCPs are implemented based on marginal p-values {p <sup>γ</sup>l :γ=1,2,l=1,2,3}**
	- **Can they be improved by considering the correlation among individual test statistics?**
- **Some assume individual test statistics are positively correlated** 
	- **May not be easily verified in some cases**
- How do we choose initial local alpha?
- **Power assessment of a MCP**

# **Joint asymptotic distribution**



$$
Z_{\nu}^{l} \prec n \left( \sqrt{\frac{N}{K+1}} \pi_{\nu l}, \hat{\sigma}_{\nu l}^{2} + \hat{\sigma}_{\nu 0}^{2} \right)
$$
  

$$
(Z_{1}, ..., Z_{pK}) \prec n \left( \sqrt{\frac{N}{K+1}} (\pi_{1}, ..., \pi_{pK})', \hat{V} \right)
$$
  

$$
\hat{V} = \begin{pmatrix} C^{0} + C^{1} & C^{0} & C^{0} \\ C^{0} & C^{0} + C^{2} & C^{0} \\ C^{0} & C^{0} & C^{0} + C^{3} \end{pmatrix}
$$

Celgene

 $C^{-1}$  = sample covariance matrix of random vector  $(Y_1^0)$ 

$$
\cdot \qquad (Y_1^l, ..., Y_p^l) \underset{7}{\longrightarrow}
$$

#### **Proposed Procedure: Overview**

- • $\bullet$  For any intersection of  $\mathsf{H}_1, \dots, \mathsf{H}_6$ ,  $\mathsf{H}(\mathsf{e})$  with **e=(e 1,…,<sup>e</sup> 6), define an α level test**
	- **Truncated Dunnett type for F 1 family**

- **Union test to maintain gatekeeping structure**
- **Joint distribution to compute local type I error**
- **Use Maucus' closed test principle to derive a strongly controlled MCP**

**Celgene**

\n**Some Notations**

\n
$$
(Z_1, \ldots, Z_{pK}) \prec n \left( \sqrt{\frac{N}{K+1}} (\pi_1, \ldots, \pi_{pK}) \right), \hat{V}
$$

\n
$$
(W_1, \ldots, W_{pK}) \prec n \left( (0, \ldots, 0) \right), \hat{V}
$$

\n
$$
U_{e, \hat{V}(e)} (u) = P \left( \max \{ W_j : e_j = 1 \} \le u \right)
$$

\n
$$
p(e) = 1 - U_{e, \hat{V}(e)} \left( \max \{ Z_j : e_j = 1 \} \right)
$$

$$
\alpha \text{ level test} \text{ for } H(e) :
$$
  

$$
\max\{ Z_j : e_j = 1 \} \ge U_{e, \hat{V}(e)} (1 - \alpha)
$$

$$
c(1, \alpha) = U_{e^M, \hat{V}(e^M)}(1 - \alpha), e^M = (1, 0, 1, 0, 1, 0)
$$

$$
f(v_1, e, \alpha) = v_1 U_{e, \hat{V}(e)} (1 - \alpha) + (1 - v_1) c (1, \alpha)
$$
  
\n
$$
\ge U_{e, \hat{V}(e)} (1 - \alpha)
$$

)

# **Dunnett-type test for F1 and for F 2**

For anye within  $F_{\rm l}$ , construct a truncated  $\alpha$  level test for H(e):  $\max\{Z_j : e_j = 1\} \ge f(\nu_1, e, \alpha)$ *e j*  $=$  1}  $\geq f(V_1, e, \alpha)$ 

Celgene

For anye within  $F_2$ , construct an un-truncated  $\max\{Z_i : e_i = 1\} \ge U_{\hat{U}(c)}(1-\alpha)$  $\alpha$  level test for H(e): ˆ $Z_i$ :  $e_i = 1$   $\ge U_{i,j}$   $(1-\alpha)^{i-j}$  $j \cdot c_j$  **i**  $j = c_{e, \hat{V}(e)}$ 

# **Union Test for Mixed Intersections**

$$
e = e^{1} + e^{2}, e^{1} \in F_{1}, e^{2} \in F_{2}
$$
  
\n
$$
H(e) = H(e^{1}) \cap H(e^{2})
$$
  
\n
$$
C(e) = \{ \max\{Z_{j} : e_{j}^{1} = 1\} \ge f(v_{1}, e^{1}, \alpha)\} \cup \{ \max\{Z_{j} : e_{j}^{2} = 1\} \ge g(v_{1}, e, \alpha)\}
$$
  
\n
$$
P(C(e) | H(e)) = \alpha \text{ for finding } g(v_{1}, e, \alpha)
$$

 $(e) = \{ \max\{Z_i : e_i^1 = 1\} \ge f(v_i, e^1, \alpha) \}$ Special case for  $e^1 = e^M$  :  $C(e) = \{ \max\{Z_j : e_j^1 = 1\} \ge f(v_1, e^1, \alpha)$  $= e^M$ 

# **Modification with Logical Constraint**

 $e = (0,1,1,0,1,1)$  with common treatment  $H(3)$ 

Celgene

 $(0,0,1,0,1,0)$  for endpoint 1 and treatment M and H  $e^1$  = (0,0,1,0,1,0) for endpoint 1 and treatment M an  $H(e) = H(e^{1}) \cap H(e^{2})$  $(0,\!1,\!0,\!0,\!0,\!1)_2$  for endpoint 2 and treatment L and H  $e^2 =$ 

 $(e) = \{ \max\{Z_i : e^1_i = 1\} \ge f(v_i, e^1, \alpha) \}$  $C(e) = \{ \max\{Z_j : e_j^1 = 1\} \ge f(v_1, e^1, \alpha)$ 

 $(0,0,1,0,1,0)$  for endpoint 1 and treatment M and H  $e = (0,1,1,0,1,0)$  without common treatment  $e^1 =$  $H(e) = H(e^{1}) \cap H(e^{2})$  $(0,1,0,0,0,0)$ , for endpoint 2 and treatment L  $0,\!0,\!1,\!0,\!1,\!0\!,\!0,\!0,\!0$ 2 $e^2 =$ 12 $(e) = \{ \max\{Z_i : e_i^1 = 1\} \ge f(v_1, e^1, \alpha)\} \cup \{ \max\{Z_i : e_i^2 = 1\} \ge g(v_1, e, \alpha)\}$  $1 \in \mathbb{R}$  1 |  $1 \in \mathbb{R}$  |  $7 \in \mathbb{Z}$ 1 $C(e) = \{ \max\{Z_j : e_j^1 = 1\} \ge f(v_1, e^1, \alpha) \} \cup \{ \max\{Z_j : e_j^2 = 1\} \ge g(v_1, e, \alpha) \}$ 



Random sample from  $(Y_1^l, Y_2^l) \prec n((m_1^l, m_2^l)^r, \Sigma^l), l = 0,1,2$ 

$$
V = \begin{pmatrix} 2.0 & -0.7 & 1.0 & 0 \\ -0.7 & 2.0 & 0 & 1.0 \\ 1.0 & 0 & 2.0 & -0.8 \\ 0 & 1.0 & -0.8 & 2.0 \end{pmatrix}
$$
  
\n
$$
Y_v^l = \sum_{j=1}^{n_l} Y_{v,j}^l, l = 0,1,2; v = 1,2, p_v = P(\sqrt{\frac{1}{\hat{\sigma}_v^2 + \hat{\sigma}_v^2}} Z_v^l > Z_v)
$$
  
\n
$$
H_i : \pi_i = 0, i = 1,2,3; F_1 = \{H_1, H_3\}, F_2 = \{H_2\}
$$
  
\nsimulation runs :10,000



# **Bonferroni Mixing**

Celgene

Reject  $H(I)$  if  $\begin{cases} p_i(I_i) \leq \alpha & \text{if } I = I_i \ (i = 1, 2), \\ \phi_I(p_1(I_1), p_2(I_2)) \leq \alpha & \text{if } I = I_1 \cup I_2, I_1 \text{ and } I_2 \text{ are nonempty.} \end{cases}$ 

$$
\phi_I(p_1(I_1), p_2(I_2)) = \min\left(p_1(I_1), \frac{p_2(I_2)}{1 - e_1(I_1|\alpha)/\alpha}\right)
$$

- • **Erro u ct o o r f nction for Bo eo nf erroni test**
	- •**Dmitrienko and Tamhane (2011) SIM**
- **Error function for truncated Hommel test**
	- $\bullet$ • Brechenmacher, Xu, Dmitrienko, Tamhane, A.C. (2011) JPS

$$
e_1(I_1|\alpha) = |I_1|\alpha/n_1 \qquad e(I|\alpha,\gamma) = (\gamma + (1-\gamma)|I|/n)\alpha \text{ if } |I| > 0
$$



#### **Application to the Clinical Trial\***

•**Population: Patients with psoriasis** 

- • **Placebo (P): n=79; Low dose regimen (L): n=66; Medium dose regimen (M): n=70; High dose regimen (H): n=72**
- • **Standardized PASI and sPGA changes adjusted by P group**
	- **Z=( ,, , , , ) 24.32 , 2.36, 38.25, 5.67, 52.77, 7.32)**
	- **V=( 78.22 7.68 42.91 3.96 42.91 3.96 7.68 1.62 3.96 0.72 3.96 0.7242.91 3.96 92.30 9.28 42.91 3.963.96 0.72 9.28 1.82 3.96 0.7242.91 3.96 42.91 3.96 96.00 7.663.96 0.72 3.96 0.72 7.66 1.64)**
- • **C(1,0.025)=22.43 and compute f(1,0.025,e), all of which are**  smaller than 23. Thus, L, M, H are better than P in PASI
- $\bullet$  **Compute g bounds and decision rules**
	- **Gatekeeping: M and H are better than P (L cannot be concluded)**
	- **Gatekeeping with constraint: same result in this case**
- \* Some design features and data are modified for illustrative purpose.

# **Graphical Approach to the trial data**



Celgene

updated graph after sequentially rejecting H11, H12, H13, H22 and H23



#### **Conclusions**

•

Celgene

#### **Propose a MCP based on jointly asymptotic multi i t ltivariate di t ib ti distribution**

- **Utilize internal correlation among marginal tests statistics**
- **Avoid assumption of normal distribution**
- **Avoid assumption of positive correlation among individual test statistics**
- **Show to have improvement over graphical procedure and bonferroni mixing for gatekeeping procedure in numerical examples under study**

#### •**Apply the procedure to a real clinical trial data**

- – **Easy implementation with computational package of multivariate normal distribution**
- • **Application to group sequential design with multiple endpoints could be extended**